We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+56.41%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$458M
AUM Growth
+$199M
Cap. Flow
+$84.3M
Cap. Flow %
18.42%
Top 10 Hldgs %
84.01%
Holding
34
New
6
Increased
5
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$29.2M
2
PTCT icon
PTC Therapeutics
PTCT
+$18.2M
3
MDCO
Medicines Co
MDCO
+$17.6M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$9.12M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$4.27M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$4.71M
2
ARRY
Array Biopharma Inc
ARRY
+$1.76M
3
RXDX
Ignyta, Inc.
RXDX
+$663K
4
AKTX
Akari Therapeutics
AKTX
+$314K
5
ARDM
Aradigm Corp Common Stock
ARDM
+$109K

Sector Composition

Rank Sector Weight
1 Healthcare 79.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
26
AnaptysBio
ANAB
$1.58B
$1.39M 0.3%
+50,000
New +$1.16M
AKTX
27
Akari Therapeutics
AKTX
$13.8M
$1.05M 0.23%
119
-56
-32% -$314K
TRAW icon
28
Traws Pharma
TRAW
$6.85M
$962K 0.21%
56
– –
ARDM
29
DELISTED
Aradigm Corp Common Stock
ARDM
$893K 0.2%
576,208
-58,500
-9% -$109K
NVET
30
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$602K 0.13%
154,840
– –
ONTXW
31
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$202K 0.04%
241,644
– –
ARRY
32
DELISTED
Array Biopharma Inc
ARRY
– –
-200,000
Closed -$1.76M
TSRO
33
DELISTED
TESARO, Inc.
TSRO
– –
-35,000
Closed -$4.71M
RXDX
34
DELISTED
Ignyta, Inc.
RXDX
– –
-125,000
Closed -$663K
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Boxer Capital held 34 positions worth $458M, up 77% from $259M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Boxer Capital deployed $84.3M of net new capital in Q1 2017, opening 6 new positions and adding to 5 existing holdings. Its largest new stake was Esperion Therapeutics: 1,275,000 shares worth $45M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 80% a quarter earlier.

On the sell side, the largest reduction was Akari Therapeutics, an estimated $314K trimmed.

  • Boxer Capital's largest Q1 2017 buy was Esperion Therapeutics: 1,275,000 shares worth $45M.
  • Boxer Capital added most to Medicines Co in Q1 2017, an estimated $17.6M increase.
  • Boxer Capital's biggest Q1 2017 reduction was Akari Therapeutics, cutting an estimated $314K.
  • Boxer Capital fully exited TESARO, Inc. in Q1 2017, selling an estimated $4.71M.
  • Boxer Capital's ten largest holdings make up 84% of its $458M portfolio in Q1 2017.
  • Boxer Capital opened 6 new positions and closed 3 in Q1 2017.
  • Boxer Capital's portfolio value rose 77% quarter-over-quarter to $458M.

Based on Boxer Capital's 13F filing for Q1 2017, filed 15 May 2017.